Evidence map›Paper›PMID 36217411›Full record

ArticleClinical, cosmetic and investigational dermatology2022

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report.

Abdullah Muqrin Al Muqrin, Abdulaziz A Alghamdi, Ziad M AlShaalan

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Abdullah Muqrin Al MuqrinDermatology, Prince Mohammed Medical City, Skaka, AlJouf, Saudi Arabia.ORCID 0000-0002-1614-9200
Abdulaziz A AlghamdiDermatology, Prince Mohammed Medical City, Skaka, AlJouf, Saudi Arabia.
Ziad M AlShaalanDepartment of Internal Medicine, College of Medicine, Jouf University, Skakak, AlJouf, Saudi Arabia.ORCID 0000-0003-3780-0725
King Saud Medical City · SAJouf University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Palmoplantar psoriasis, a clinical variant of plaque psoriasis, has a significant impact by causing deterioration in the social and functional aspects of patients' lives. Numerous therapeutic interventions are available for palmoplantar psoriasis. Although emerging biological agents have had an enormous positive impact on chronic plaque psoriasis, studies assessing their effectiveness in the palmoplantar phenotype are limited in the literature. We therefore present a case report of a patient with a 10-year history of palmoplantar psoriasis, which has significantly impacted her occupational life. She was treated with Risankizumab, showing a significant and rapid improvement in her symptoms. We believe that Risankizumab could be one of the most effective therapeutic interventions in the clinical context where rapid clearance of palmoplantar psoriasis is required.

Indexed as

biologicbiological agentpalmoplantarpsoriasisrapid onsetRisankizumab

Identifiers

PMID36217411
PMCPMC9547619
OpenAlexW4301397786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.